Expression of e-cadherin in high-risk breast cancer

Journal of Cancer Research and Clinical Oncology

Volumn 131, Issue 1, 2005, Pages 14-18

  Howard, Eugene M ^a   Lau, Stephen K ^b   Lyles, Robert H ^c   Birdsong, George G ^b   Umbreit, Jay N ^a   Kochhar, Ruby ^a  

^a EMORY UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c EMORY UNIVERSITY   (United States)

Author keywords

Aggressive breast carcinoma; E cadherin; HER 2; HIF 1 ; Immunohistochemistry; p53; VEGF

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PROGESTERONE RECEPTOR; PROTEIN P53; UVOMORULIN; VASCULOTROPIN; ESTROGEN RECEPTOR;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; BREAST CANCER; CANCER RISK; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; HUMAN; HYPOXIA; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SOCIOECONOMICS; CANCER STAGING; CANCER SURVIVAL; DISEASE COURSE; DOWN REGULATION; REVIEW; SOCIAL STATUS; TUMOR VOLUME;

ADULT; AGED; ANALYSIS OF VARIANCE; BREAST NEOPLASMS; CADHERINS; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOHISTOCHEMISTRY; LOGISTIC MODELS; LYMPHATIC METASTASIS; MIDDLE AGED; ODDS RATIO; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RISK ASSESSMENT; RISK FACTORS; SURVIVAL ANALYSIS; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 11244354303     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-004-0618-z     Document Type: Article

References (21)

1. Adam L, Vadlamudi R, Kondapaka SB, Chernoff J, Mendelsohn J, Kumar R (1998) Hergulin regulates cytoskeletal reorganization and cell migration through the p21-activated kinase-1 via phosphatidylinositol-3 kinase. J Biol Chem 273:28238-28246
2. Asgeirsson KS, Jonasson JG, Tryggvaottir L, Olafsdottir K, Sigurgeirsdottir JR, Ingvarsson S, Ogmundsdottir HM (2000) Altered expression of e-cadherin in breast cancer: patterns, mechanisms and clinical significance. Eur J Cancer 36:1098-1106
3. Bankfalvi A, Terpe HJ, Breukelmann D, Bier B, Rempe D, Pschadka G, Krech R, Lelle RJ, Boecker W (1999) Immunophenotypic and prognostic analysis of E-cadherin and beta-catenin expression during breast carcinogenesis and tumour progression: a comparative study with CD44. Histopath 34:25-34
4. Bukholm IK, Nesland JM, Karensen R, Jacobsen U, Borresen-Dale AL (1997) Expression of e-cadherin and its relation to the p53 protein status in human breast carcinomas. Virchows Arch 431:317-321
5. Charpin C, Garcia S, Bouvier C, Devictor B, Andrac L, Choux R, Lavaut M (1997) E-cadherin quantitative immunocytochemical assays in breast carcinomas. J Pathol 181:294-300
6. Colpaert CG, Vermeulen PB, Benoy I, Soubry A, van Beest P, Goovaerts G, Dirix LY, Van Dam P, Fox SB, Harris AL, Van Maarck EA (2003) Inflammatory breast cancer shows angiogenesis with high endothelial proliferation rate and strong e-cadherin expression. Br J Cancer 88:718-725
7. D'Souza B, Taylor-Papdimitrou J (1994) Over-expression of ERBB2 in human mammary epithelial cells signals inhibition of transcription of the E-CD gene. Proc Natl Acad Sci 91:7202-7206
8. Elzagheid A, Kuopio T, Ilmen M, Collan Y (2002) Prognostication of invasive ductal breast cancer by quantification of e-cadherin immunostaining: the methodology and clinical relevance. Histopath 41:127-133
9. Fearon ER (2003) Connecting estrogen receptor function, transcriptional repression, and e-cadherin expression in breast cancer. Cancer Cell 3:307-310
10. Gillett CE, Miles DW, Ryder K, Skilton D, Liebman RD, Springall RJ, Barnes DM, Hanby AM (2001) Retention of the expression of E-cadherin and catenins is associated with shorter survival in grade III ductal carcinoma of the breast. J Pathol 193:433-441
11. Heimann R, Lan F, McBride R, Hellman S (2000) Separating favorable from unfavorable prognostic markers in breast cancer: the role of e-cadherin. Cancer Res 60:298-304
12. Jiang WG, Mansel RE (2000) E-cadherin complex and its abnormalities in human breast cancer. Surg Onc 9:151-171
13. Kemler R (1993) From cadherins to catenins: cytoplasmic protein interactions and regulation of cell adhesion. Trends Genet 9:317-321
14. Kleer CG, van Golen KL, Braun T, Merajver SD (2001) Persistent e-cadherin expression in inflammatory breast cancer. Modern Path 14:458-463
15. Kochhar R, Howard EM, Tadros TS, Birdsong GG, Lyles RH, Lau SK (2003) Correlation of p53, her2neu, vascular endothelial growth factor (VEGF) and e-cadherin expression in adenocarcinoma of breast. Proc AACR 6213
16. Nakopoulou L, Gakiopoulou-Givalou H, Karayiannakis AJ, Giannopoulou I, Keramopoulos A, Davaris P, Pignatelli M (2002) Abnormal alpha-catenin expression in invasive breast cancer correlates with poor patient survival. Histopath 40:536-546
17. Palacios J, Benito N, Pizarro A, Limeres MA, Suarez A, Cano A, Gamallo C (1997) Relationship between ERBB2 and e-cadherin expression in human breast cancer. Virchows Arch 427:259-263
18. Parker C, Rampaul RS, Pinder SE, Bell JA, Wencyk PM, Blamey RW, Nicholson RI, Robertson JF (2001) E-cadherin as a prognostic indicator in primary breast cancer. Br J Cancer 85:1958-1963
19. Rose DP, Royak-Schaler, R (2001) Tumor biology and prognosis in black breast cancer: a review. Cancer Det Prev 25:16-31
20. Zhong H, Chiles K, Feldser D, Laughner E, Hanrahan C, Georgescu MM, Simons JW, Semenza GL (2000) Modulation of HIF-1α expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 60:1541-1545
21. Zschiesche W, Schonborn I, Behrens J, Herrenknecht K, Hartveit F, Lilleng P, Birchmeier W (1997) Expression of e-cadherin and catenins in invasive mammary carcinomas. Anticancer Res 17:561-567